Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer.

ABSTRACT: Drug resistance is always a great obstacle in any endocrine therapy of breast cancer. Although the combination of endocrine therapy and targeted therapy has been shown to significantly improve prognosis, refractory endocrine resistance is still common. Dysregulation of the Hippo pathway is often related to the occurrence and the development of many tumors. Targeted therapies of this pathway have played important roles in the study of triple negative breast cancer (TNBC). Targeting the Hippo pathway in combination with chemotherapy or other targeted therapies has been shown to significantly improve specific antitumor effects and reduce cancer antidrug resistance. Further exploration has shown that the Hippo pathway is closely related to endocrine resistance, and it plays a "co-correlation p

SUBMITTER: Chen J 

PROVIDER: S-EPMC8194146 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature